STADA ARZNEIMITTEL
DGAP-Ad-hoc: STADA Arzneimittel AG / Key word(s): Miscellaneous
Bad Vilbel, February 1, 2018 - The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2018. Peter Goldschmidt will take over from Dr. Claudio Albrecht who has been the CEO at STADA since September 27, 2017. Since 2013, Peter Goldschmidt serves as the President and Head of North America at Sandoz Inc., responsible for the Company's North American operations. Mark Keatley, Chief Financial Officer, and Dr. Barthold Piening, Chief Technical Officer, will keep their positions on the STADA Executive Board. Contact: STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-Mail: leslie.iltgen@stada.de or visit us online on www.stada.de.
01-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | STADA Arzneimittel AG |
| Stadastraße 2-18 | |
| 61118 Bad Vilbel | |
| Germany | |
| Phone: | +49 (0)6101 603- 113 |
| Fax: | +49 (0)6101 603- 506 |
| E-mail: | communications@stada.de |
| Internet: | www.stada.de |
| ISIN: | DE0007251803, DE0007251845, |
| WKN: | 725180, 725184, |
| Indices: | MDAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| End of Announcement | DGAP News Service |
650425 01-Feb-2018 CET/CEST
